KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Current Deferred Revenue (2016 - 2023)

Halozyme Therapeutics (HALO) has disclosed Current Deferred Revenue for 14 consecutive years, with $3.1 million as the latest value for Q2 2023.

  • On a quarterly basis, Current Deferred Revenue fell 54.95% to $3.1 million in Q2 2023 year-over-year; TTM through Jun 2023 was $3.1 million, a 54.95% decrease, with the full-year FY2022 number at $5.5 million, up 214.95% from a year prior.
  • Current Deferred Revenue was $3.1 million for Q2 2023 at Halozyme Therapeutics, down from $5.5 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $6.9 million in Q2 2022 to a low of $1.2 million in Q2 2021.
  • A 5-year average of $3.8 million and a median of $3.8 million in 2019 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 450.92% in 2022; the steepest drop was 69.75% in 2022.
  • Halozyme Therapeutics' Current Deferred Revenue stood at $4.0 million in 2019, then tumbled by 56.48% to $1.7 million in 2020, then changed by 0.0% to $1.7 million in 2021, then skyrocketed by 214.95% to $5.5 million in 2022, then tumbled by 43.72% to $3.1 million in 2023.
  • Per Business Quant, the three most recent readings for HALO's Current Deferred Revenue are $3.1 million (Q2 2023), $5.5 million (Q1 2023), and $5.5 million (Q4 2022).